News and Trends 2 Apr 2020 iTeos Therapeutics’ Cancer Immunotherapy Boosted with €114M Funding …iTeos, explained to me that both of its immunotherapy candidates target key resistance mechanisms that tumors develop against anti-cancer drugs known as immune checkpoint inhibitors. iTeos’ lead candidate drug does… April 2, 2020 - 3 minutesmins - By Laura Cowen Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 Aelis Farma’s first trial for cognitive disorder drug for Down Syndrome patients …candidate for the treatment of cognitive disorders. Aelis Farma is a clinical stage biopharmaceutical company specializing in the development of treatments for brain diseases, made the announcement today (November 15)…. November 15, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Feb 2023 AAHI bags $9.9M to develop nasal spray influenza RNA vaccine …develop a prototype intranasal bivalent influenza RNA vaccine candidate. The candidate will be based on AAHI’s self-amplifying RNA (saRNA) platform, which targets both pandemic A(H5N1) and A(H7N9) influenza virus pathogens…. February 7, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 9 Dec 2024 CAR-T cell therapy for lupus: An emerging field with great potential …bring this type of therapy to the market, potentially offering a cure for the disease. So far, though, candidates are still working their way through the clinic trials, and a… December 9, 2024 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2023 Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation Infex Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted qualified infectious disease product (QIDP) designation to MET-X, the company’s broad spectrum metallo-beta-lactamase (MBL) inhibitor. Infex… January 4, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 18 Apr 2024 5 RNA editing companies you should know about …rare and common diseases. It is currently working on advancing its first therapeutic program, a best-in-class product candidate to treat the inherited genetic disease alpha-1 antitrypsin deficiency (AATD), as well… April 18, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
More News! 8 Feb 2017 The First Stroke Drug in Decades? French Biotech gets closer to the Clinic …Medicine & Healthcare products Regulatory Agency (MHRA) received in January. Acticor’s candidate, ACT017, is a humanized antibody fragment (Fab) that inhibits the activity of platelet glycoprotein VI (GPVI). This strategy… February 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jan 2020 Adaptimmune to Take Off-The-Shelf CAR-T to Phase I with Astellas The UK biotech Adaptimmune Therapeutics has inked a deal worth up to €806M with Japanese Astellas Pharma to complete phase I trials of candidate off-the-shelf T-cell therapies for cancer including… January 15, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jan 2018 Swedish Biotech Can Now Fast-Track its Metabolic Disorder Drug …addition, the company’s candidate has received Fast Track status from the FDA, which will help the candidate move into the clinic in 2018. Sanfilippo A syndrome is a life-threatening inherited… January 23, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 12 Feb 2024 RNA editing set to take off: could DNA’s short-lived cousin overcome the limitations of CRISPR gene editing? …its RNA editing candidate, WVE-006. This was accepted, and dosing for that trial has now begun in the U.K., marking the first time an RNA editing candidate has reached the… February 12, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 16 Nov 2022 Six biotech stocks trading below cash right now …result, Atea plans to test its lead candidate antiviral in a phase 3 trial by the end of 2022. The trial will recruit at least 1,500 high-risk, non-hospitalized patients with… November 16, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2017 This Herpes Cure is Proving to Work Better than its Predecessors …completed a Phase II trial in which its candidate pritelivir outperformed the current standard care for genital herpes. When compared to the antiviral drug valacyclovir, the candidate reduced virus shedding,… January 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email